DURHAM, N.C., APRIL 20, 2018 — A Premier Research oncology expert will discuss advances in the development of cancer drugs at Clinical Operations in Oncology Trials West Coast in Burlingame, California.
Brian Huber, Executive Director for Oncology Strategic Development, will present Transforming the Oncology Drug Development Process on Tuesday, April 24, at 10 a.m. Mr. Huber will discuss how, despite notable successes in treating certain cancers (testicular among them), other cancers remain resistant to all current treatment regimens — exposing a need to bring better medicines to these patients more quickly and cost-effectively.
Topics will include:
- How, in light of ever-expanding drug development costs, the oncology drug development process must transform to bring innovative medicines to patients faster, at lower cost, and with a higher probability of success.
- The need to combine oncology precision medicine with the adaptability and flexibility increasingly championed by the FDA.
- Recent examples of innovation in oncology drug development.
Premier Research is a principal sponsor of Clinical Operations in Oncology Trials West Coast, an annual gathering of pharma and biotech professionals.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,250 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.